PHC Holdings Co., Ltd. (Headquarters: Minato-ku, Tokyo, hereinafter referred to as 'PHCHD') has decided that Kyoko Deguchi will be appointed as the company's representative director, president and chief executive officer (CEO) on April 1, 2024.

So I would like to inform you.

Masatsugu Miyazaki will step down from his duties as Representative Director, President and Chief Executive Officer (CEO) on March 31st, and will continue to serve as a director until the general meeting of shareholders to be held in June.

Mr. Deguchi, who is currently an independent director of the Company, has over 20 years of experience in the healthcare and chemical industries, and has previously served as head of the Japanese subsidiary of various global healthcare companies, including Janssen Pharmaceuticals, Stryker, and AbbVie. He has held senior positions in finance, marketing, etc. Currently, he is involved in management as the vice director of rehabilitation orthopedics, and has experience as an outside director at multiple listed and unlisted companies, including T-Gaia Co., Ltd. and Heartseed Co., Ltd.

Miyazaki says: 'Since I assumed the position of president in April 2022, I have reorganized the PHC Group's business structure for growth.I have revised the PHC Group's medium-term management plan, the 'Value Creation Plan,' and have revised the PHC Group's 'individual We have been promoting the expansion of 'chemical diagnosis solutions' and 'digital health solutions,' as well as accelerating our 'advanced treatment development solutions.' Although we have achieved a certain level of results, it has been difficult to achieve the expected results with our growth measures. It will still take some time, and results were lower than expected due to changes in the business environment.We feel that we need to strive for further innovation and efficiency as a group.Therefore, we will strengthen our global responsiveness with a new structure. I decided to do it.

We are confident that Mr. Deguchi, who has extensive experience in the healthcare industry and expertise in business operations, will lead the future growth of PHC Group. I will provide full support to Mr. Deguchi over the coming months as he works to achieve further growth and business expansion for the PHC Group. '

Exit says: 'As PHCHD's Representative Director, President and CEO, I sincerely accept the opportunity to contribute to the healthcare industry. PHCHD went public in 2021 with three business segments as its pillars. We recognize that the challenge is how to create the same.In order to increase the sense of unity within the PHC Group, which is expanding its business globally, we need to raise awareness of 'ONE PHC' and develop global human resources. We will strive to create new value for all people who desire good health, which is the management philosophy of the PHC Group.'

Ivan Tornos, an independent director and member of PHCHD's Nomination and Compensation Committee, said: 'I would like to express my deepest gratitude to Mr. Miyazaki, who has promoted structural reforms and transformation of our company and laid the foundation for us to become a listed company, and I wish him all the best in his future endeavors.As an independent outside director, he has supported the growth of our group. Mr. Taguchi is a manager who listens to diverse opinions and responds flexibly to changes in the environment.The Company will further advance its medium-term management plan in order to achieve growth, innovation, and efficiency improvements on a global scale. I will.'

About PHC Holdings Co., Ltd.>

PHC Holdings Corporation (stock code: 6523 TSE Prime) is a global healthcare company whose management philosophy is to create new value for all people who desire good health and contribute to the creation of a prosperous society. We have PHC Corporation, Ascensia Diabetes Care Holdings, Epredia Holdings, LSI Medience Co., Ltd., Weemex Co., Ltd., and Mediford Co., Ltd. under our umbrella, and operate in the business areas of diabetes management, healthcare solutions, diagnostics and life sciences. We develop, manufacture, sell, and service. Consolidated revenue in fiscal 2022 will be 356.4 billion yen, and our products and services are used by customers in more than 125 countries and regions around the world. PHC Group is the collective name for PHC Holdings Corporation and its operating subsidiaries.

Contact:

Tel: 03-6778-5311

Email: phc-pr@gg.phchd.com

(C) 2024 Electronic News Publishing, source ENP Newswire